Stay updated on Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedFooter now shows Revision: v3.5.2, replacing Revision: v3.5.0. This is a technical update with no impact on study information or user actions.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' as a listed condition in the study details.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision v3.5.0 added; revision v3.4.3 removed.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedAdded Revision: v3.4.2; removed the government funding lapse notice and the older Revision: v3.4.1 entry.SummaryDifference0.4%

- Check81 days agoChange DetectedThe page now displays a government funding lapse notice and the site version was updated to Revision: v3.4.1, which are administrative updates and do not affect core study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab plus Vorinostat in Head and Neck Cancer Clinical Trial page.